THE LOOK AHEAD
Halberd is finalizing the arrangements with Mississippi State University to develop and conduct an animal testing protocol for Halberd's patent-pending nasal spray to safely counteract the effects of Traumatic Brain Injury.
Halberd has the option to consider loans to complete the required audits and the QB up-list. However, Halberd's Articles of Incorporation preclude the issuance of any convertible promissory notes, convertible preferred stock or other convertible instruments. Halberd has chosen to remain as "OTC Markets Pink Sheets" for the near-term.
Halberd is about to embark on a huge previously unannounced expansion of its capability to eradicate multiple antibiotic-resistant bacteria with a single proprietary antibody. While that will require a major focus by Halberd, it offers the largest potential short-term payback to the company and its stockholders.
Halberd's goal has always been to either secure a significant government contract or partner with Big Pharma, because it did not have the huge quantity of funds necessary to secure FDA approval for its products or processes.
Government contracts and Big Pharma are not concerned with a company's stock exchange listing; they are focused on the content of the technology being evaluated. With each accomplishment, Halberd moves closer to finalizing a potential government contract and suitable terms for an agreement with Big Pharma.
Leadership is about making tough decisions using the facts to obtain optimum results. Halberd believes that its interests are best served for the short-term by investing its available resources to advance our technology through R&D and put Halberd in a better position to secure a potential government contract and/or a relationship with Big Pharma.
Bullish
News 
Market Data 
Discover 
